Immuno-oncology trends: preclinical models, biomarkers, and clinical development

The landscape in immuno-oncology (I-O) has undergone profound changes since its early beginnings up through the rapid advances happening today. The current drug development pipeline consists of thousands of potential I-O therapies and therapy combinations, many of which are being evaluated in clinic...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2022-01, Vol.10 (1), p.e003231
Main Authors: Franklin, Maryland Rosenfeld, Platero, Suso, Saini, Kamal S, Curigliano, Giuseppe, Anderson, Steven
Format: Article
Language:English
Subjects:
antigenic modulation
Antigens
Biomarkers
Biomarkers, Tumor - metabolism
Cancer
Cell culture
Clinical trials
clinical trials as topic
Cytokines
Cytotoxicity
Drug development
Genes
Genetic engineering
Genomes
Humans
Immune system
immune tolerance
Immunotherapy
Immunotherapy - methods
Medical Oncology
Medical research
Mutation
Neoplasms - drug therapy
Oncology
Pharmacodynamics
Review
Rodents
tumor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The landscape in immuno-oncology (I-O) has undergone profound changes since its early beginnings up through the rapid advances happening today. The current drug development pipeline consists of thousands of potential I-O therapies and therapy combinations, many of which are being evaluated in clinical trials. The efficient and successful development of these assets requires the investment in and utilization of appropriate tools and technologies that can facilitate the rapid transitions from preclinical evaluation through clinical development. These tools include (i) appropriate preclinical models, (ii) biomarkers of pharmacodynamic, predictive and monitoring utility, and (iii) evolving clinical trial designs that allow rapid and efficient evaluation during the development process. This article provides an overview of how novel discoveries and insights into each of these three areas have the potential to further address the clinical management needs for patients with cancer.
ISSN:2051-1426
2051-1426
DOI:10.1136/jitc-2021-003231